After 2016, the cardiorenal protective effects demonstrated by two promising glucose-lowering drug classes, the SGLT2is and GLP-1 RAs, have recently changed the treatment of CV and renal complications of diabetes (49, 50) (Figure 2). Here, GLP1R is linked to diabetes mellitus.